Cargando…

Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?

OBJECTIVES: To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc resection of bladder tumour (ERBT) for pathological T1 (pT1) bladder cancer. PATIENTS AND METHODS: We retrospectively analysed the record of 106 patients with pT1 high‐g...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagisawa, Takafumi, Sato, Shun, Hayashida, Yasushi, Okada, Yohei, Iwatani, Kosuke, Matsukawa, Akihiro, Kimura, Takahiro, Takahashi, Hiroyuki, Egawa, Shin, Shariat, Shahrokh F., Miki, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084154/
https://www.ncbi.nlm.nih.gov/pubmed/35488409
http://dx.doi.org/10.1111/bju.15760
_version_ 1785021677394984960
author Yanagisawa, Takafumi
Sato, Shun
Hayashida, Yasushi
Okada, Yohei
Iwatani, Kosuke
Matsukawa, Akihiro
Kimura, Takahiro
Takahashi, Hiroyuki
Egawa, Shin
Shariat, Shahrokh F.
Miki, Jun
author_facet Yanagisawa, Takafumi
Sato, Shun
Hayashida, Yasushi
Okada, Yohei
Iwatani, Kosuke
Matsukawa, Akihiro
Kimura, Takahiro
Takahashi, Hiroyuki
Egawa, Shin
Shariat, Shahrokh F.
Miki, Jun
author_sort Yanagisawa, Takafumi
collection PubMed
description OBJECTIVES: To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc resection of bladder tumour (ERBT) for pathological T1 (pT1) bladder cancer. PATIENTS AND METHODS: We retrospectively analysed the record of 106 patients with pT1 high‐grade bladder cancer who underwent ERBT between April 2013 and February 2021 at multiple institutions. All specimens were reviewed by a genitourinary pathologist. The primary outcome measures were recurrence‐free survival (RFS) and progression‐free survival (PFS) between patients with and those without reTUR. We also analysed the predictive value of surgical margin on the likelihood of residual tumour on reTUR. RESULTS: A reTUR was performed in 50 of the 106 patients. The 2‐year RFS and 3‐year PFS were comparable between patients who underwent reTUR and those who did not (55.1% vs 59.9%, P = 0.6, 80.6% vs 82.6%, P = 0.6, respectively). No patient was upstaged to pT2 on reTUR. Regarding the surgical margin status, there were no recurrences at the original site in 51 patients with negative horizontal margins. Cox proportional hazard analysis revealed that a positive vertical margin was an independent prognostic factor of worse PFS. On reTUR, six pTa/is residues were detected in patients with a positive horizontal margin, and three pT1 residues were detected in one patient with a positive vertical margin or other adverse pathological features. CONCLUSIONS: A reTUR after ERBT for pT1 bladder cancer appears not to improve either recurrence or progression. Surgical margin status affects prognosis and reTUR outcomes. A reTUR can be omitted after ERBT in patients with pT1 bladder cancer and negative margins; for those with positive horizontal or vertical margins, reTUR should remain the standard until proven otherwise.
format Online
Article
Text
id pubmed-10084154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100841542023-04-11 Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer? Yanagisawa, Takafumi Sato, Shun Hayashida, Yasushi Okada, Yohei Iwatani, Kosuke Matsukawa, Akihiro Kimura, Takahiro Takahashi, Hiroyuki Egawa, Shin Shariat, Shahrokh F. Miki, Jun BJU Int Original Articles OBJECTIVES: To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc resection of bladder tumour (ERBT) for pathological T1 (pT1) bladder cancer. PATIENTS AND METHODS: We retrospectively analysed the record of 106 patients with pT1 high‐grade bladder cancer who underwent ERBT between April 2013 and February 2021 at multiple institutions. All specimens were reviewed by a genitourinary pathologist. The primary outcome measures were recurrence‐free survival (RFS) and progression‐free survival (PFS) between patients with and those without reTUR. We also analysed the predictive value of surgical margin on the likelihood of residual tumour on reTUR. RESULTS: A reTUR was performed in 50 of the 106 patients. The 2‐year RFS and 3‐year PFS were comparable between patients who underwent reTUR and those who did not (55.1% vs 59.9%, P = 0.6, 80.6% vs 82.6%, P = 0.6, respectively). No patient was upstaged to pT2 on reTUR. Regarding the surgical margin status, there were no recurrences at the original site in 51 patients with negative horizontal margins. Cox proportional hazard analysis revealed that a positive vertical margin was an independent prognostic factor of worse PFS. On reTUR, six pTa/is residues were detected in patients with a positive horizontal margin, and three pT1 residues were detected in one patient with a positive vertical margin or other adverse pathological features. CONCLUSIONS: A reTUR after ERBT for pT1 bladder cancer appears not to improve either recurrence or progression. Surgical margin status affects prognosis and reTUR outcomes. A reTUR can be omitted after ERBT in patients with pT1 bladder cancer and negative margins; for those with positive horizontal or vertical margins, reTUR should remain the standard until proven otherwise. John Wiley and Sons Inc. 2022-05-13 2023-02 /pmc/articles/PMC10084154/ /pubmed/35488409 http://dx.doi.org/10.1111/bju.15760 Text en © 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Yanagisawa, Takafumi
Sato, Shun
Hayashida, Yasushi
Okada, Yohei
Iwatani, Kosuke
Matsukawa, Akihiro
Kimura, Takahiro
Takahashi, Hiroyuki
Egawa, Shin
Shariat, Shahrokh F.
Miki, Jun
Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title_full Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title_fullStr Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title_full_unstemmed Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title_short Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
title_sort do we need repeat transurethral resection after en bloc resection for pathological t1 bladder cancer?
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084154/
https://www.ncbi.nlm.nih.gov/pubmed/35488409
http://dx.doi.org/10.1111/bju.15760
work_keys_str_mv AT yanagisawatakafumi doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT satoshun doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT hayashidayasushi doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT okadayohei doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT iwatanikosuke doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT matsukawaakihiro doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT kimuratakahiro doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT takahashihiroyuki doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT egawashin doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT shariatshahrokhf doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer
AT mikijun doweneedrepeattransurethralresectionafterenblocresectionforpathologicalt1bladdercancer